We are studying a new medication, NVL-655, for patients with advanced ALK-positive lung cancer who haven't been treated before. The goal is to see if it works better and is safer than the current standard treatment, alectinib.
Health conditions and diseases that the clinical trial is designed to study and treat.
Advanced ALK-positive non-small cell lung cancer (NSCLC) is a type of lung cancer that has spread beyond the lungs and is characterized by a mutation in the ALK gene, which can affect treatment options.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
